---
title: "Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Safety questions"
description: "Safety questions on Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Warnings. Questions: What are the most common side effects of Verzenio in early breast cancer? What lab abnormalities occur with Verzenio in early breast cancer (monarchE)? Does Verzenio cause hair loss in early breast cancer? What serious side effects occurred with Verzenio in monarchE? 4 further questions follow. 8 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Safety questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)

Safety questions that apply to every indication of Verzenio are on [Verzenio (abemaciclib), all indications: Safety](https://www.evicenter.com/medical-information/verzenio/safety).

## Side effects

<a id="verzenio-side-effects"></a>

### What are the most common side effects of Verzenio in early breast cancer?

> “The most common (>20%) adverse reactions, including laboratory abnormalities in the VERZENIO plus tamoxifen or an aromatase inhibitor arm and ≥2% higher than the tamoxifen or an aromatase inhibitor arm were: increased creatinine, decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, infections, fatigue, increased alanine aminotransferase (ALT), decreased platelets, increased aspartate aminotransferase (AST), nausea, and headache.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=The%20most%20common%20%28%3E20%25%29%20adverse,aminotransferase%20%28AST%29%2C%20nausea%2C%20and%20headache.)

> “Table 8: Adverse Reactions (≥10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE
>
> a Adverse reactions were graded using NCI CTCAE version 4.0
>
>
>
>
> b Includes other related terms.
>
>
>
>
> Adverse Reactiona	VERZENIO Plus
> Tamoxifen or an Aromatase Inhibitor
> N=2791	Tamoxifen or an Aromatase Inhibitor
> N=2800
> All Grades
> %	Grade 3
> %	Grade 4
> %	All Grades
> %	Grade 3
> %	Grade 4
> %
> Gastrointestinal Disorders
>      Diarrhea	84	8	0	9	0.2	0
>      Nausea	30	0.5	0	9	<0.1	0
>      Vomiting	18	0.5	0	4.6	0.1	0
>      Stomatitisb	14	0.1	0	5	0	0
> Infections and Infestations
>      Infectionsb	51	4.9	0.6	39	2.7	0.1
> General Disorders and Administration Site Conditions
>      Fatigueb	41	2.9	0	18	0.1	0
> Nervous System Disorders
>      Headache	20	0.3	0	15	0.2	0
>      Dizziness	11	0.1	0	7	<0.1	0
> Metabolism and Nutrition Disorders
>      Decreased appetite	12	0.6	0	2.4	<0.1	0
> Skin and Subcutaneous Tissue Disorders
>      Rashb	11	0.4	0	4.5	0	0
>      Alopecia	11	0	0	2.7	0	0”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%208%3A%20Adverse%20Reactions%20%28%E2%89%A510%25%29,0)

> “Clinically relevant adverse reactions in <10% of patients who received VERZENIO in combination with tamoxifen or an aromatase inhibitor in monarchE include: pruritus (9%), dyspepsia (8%), nail disorder (6%), increased lacrimation (6%), dysgeusia (5%), ILD/pneumonitis (3%), and VTE (3%).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Clinically%20relevant%20adverse%20reactions%20in,ILD%2Fpneumonitis%20%283%25%29%2C%20and%20VTE%20%283%25%29.)

Note: Columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2791: all grades, Grade 3, Grade 4) followed by tamoxifen or an aromatase inhibitor alone (N=2800: all grades, Grade 3, Grade 4), in percent, as in the table header.

<a id="verzenio-lab-abnormalities"></a>

### What lab abnormalities occur with Verzenio in early breast cancer (monarchE)?

> “Table 9: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE
> 	VERZENIO
> Plus Tamoxifen or an Aromatase Inhibitor
> N=2791	Tamoxifen or an Aromatase Inhibitor
> N=2800
> All Grades
> %	Grade 3
> %	Grade 4
> %	All Grades
> %	Grade 3
> %	Grade 4
> %
> Chemistry
> Creatinine increased	99	0.5	0	91	<0.1	0
> ALT increased	37	2.5	<0.1	24	1.2	0
> AST increased	31	1.5	<0.1	18	0.9	0
> Potassium decreased	11	1.2	0.1	3.8	0.1	0.1
> Hematology
> Neutrophils decreased	84	18	0.7	23	1.6	0.3
> Hemoglobin decreased	68	1	0	17	0.1	0
> Lymphocytes decreased	59	13	0.2	24	2.4	0.1
> Platelets decreased	37	0.7	0.2	10	0.1	0.1”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%209%3A%20Laboratory%20Abnormalities%20%28%E2%89%A510%25%29,0.1)

Note: Columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2791: all grades, Grade 3, Grade 4) followed by tamoxifen or an aromatase inhibitor alone (N=2800: all grades, Grade 3, Grade 4), in percent.

<a id="verzenio-hair-loss"></a>

### Does Verzenio cause hair loss in early breast cancer?

> “Table 8: Adverse Reactions (≥10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%208%3A%20Adverse%20Reactions%20%28%E2%89%A510%25%29,Arms%20of%20%E2%89%A52%25%5D%20in%20monarchE)

> “Adverse Reactiona	VERZENIO Plus
> Tamoxifen or an Aromatase Inhibitor
> N=2791	Tamoxifen or an Aromatase Inhibitor
> N=2800
> All Grades
> %	Grade 3
> %	Grade 4
> %	All Grades
> %	Grade 3
> %	Grade 4
> %”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Adverse%20Reactiona,Grade%204)

> “Alopecia	11	0	0	2.7	0	0”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Alopecia,0)

Note: Columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2791: all grades, Grade 3, Grade 4) followed by tamoxifen or an aromatase inhibitor alone (N=2800: all grades, Grade 3, Grade 4), in percent, as in the table header.

<a id="verzenio-serious-side-effects"></a>

### What serious side effects occurred with Verzenio in monarchE?

> “Serious adverse reactions occurred in 15% of patients who received VERZENIO in combination with endocrine therapy (tamoxifen or an aromatase inhibitor). Serious adverse reactions in ≥1% of patients included venous thromboembolism (VTE) (1.2%) and pneumonia (1%). Fatal adverse reactions occurred in 0.8% of patients who received VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor), including: cardiac failure (0.1%), cardiac arrest, myocardial infarction, ventricular fibrillation, cerebral hemorrhage, cerebrovascular accident, pneumonitis, hypoxia, diarrhea, and mesenteric artery thrombosis (0.03% each).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Serious%20adverse%20reactions%20occurred%20in,mesenteric%20artery%20thrombosis%20%280.03%25%20each%29.)

<a id="verzenio-discontinuation"></a>

### How often was Verzenio stopped or reduced for side effects (monarchE)?

> “Permanent discontinuation of VERZENIO due to an adverse reaction occurred in 19% of patients. Adverse reactions which resulted in permanent discontinuation in >1% of patients were diarrhea (5%), and fatigue (2%).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Permanent%20discontinuation%20of%20VERZENIO%20due,diarrhea%20%285%25%29%2C%20and%20fatigue%20%282%25%29.)

> “19% of patients discontinued Verzenio + ET due to ARs vs 1% of patients who discontinued treatment on ET alone due to ARs<sup>1</sup>”

Source: [VERZENIO: Adverse Reactions | HCP Safety, captured 2026-11-14](https://verzenio.lilly.com/hcp/safety-adverse-reactions#:~:text=19%25%20of%20patients%20discontinued%20Verzenio,on%20ET%20alone%20due%20to)

> “Dosage interruptions of VERZENIO due to an adverse reaction occurred in 62% of patients. Adverse reactions which required dosage interruptions in ≥5% of patients were diarrhea (20%), neutropenia (16%), leukopenia (7%), and fatigue (5%).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Dosage%20interruptions%20of%20VERZENIO%20due,leukopenia%20%287%25%29%2C%20and%20fatigue%20%285%25%29.)

> “Dose reductions of VERZENIO due to an adverse reaction occurred in 44% of patients. Adverse reactions which required dose reductions in ≥5% of patients were diarrhea (17%), neutropenia (8%), and fatigue (5%).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Dose%20reductions%20of%20VERZENIO%20due,neutropenia%20%288%25%29%2C%20and%20fatigue%20%285%25%29.)

<a id="verzenio-diarrhea"></a>

### How common is diarrhea with Verzenio in early breast cancer?

> “In monarchE, diarrhea occurred in 84% of patients with Verzenio plus ET vs 9% with ET alone (N=5,637). 76% of patients experienced Grade 1 or 2 diarrhea. 8% of patients experienced Grade 3 diarrhea. No patients experienced Grade 4 diarrhea.<sup>3</sup>”

Source: [VERZENIO: Diarrhea Management | HCP Safety, captured 2026-11-14](https://verzenio.lilly.com/hcp/safety-managing-diarrhea#:~:text=In%20monarchE%2C%20diarrhea%20occurred%20in,No%20patients%20experienced%20Grade%204)

> “The monarchE study included one death associated with diarrhea.<sup>3</sup>”

Source: [VERZENIO: Diarrhea Management | HCP Safety, captured 2026-11-14](https://verzenio.lilly.com/hcp/safety-managing-diarrhea#:~:text=The%20monarchE%20study%20included%20one%20death%20associated%20with)

> “Time to onset: 8 days<sup>1</sup> (median, first event of any grade)
>
> Duration: 5-6 days<sup>1</sup> (median, Grade 2 or Grade 3 event)”

Source: [VERZENIO: Diarrhea Management | HCP Safety, captured 2026-11-14](https://verzenio.lilly.com/hcp/safety-managing-diarrhea#:~:text=Time%20to%20onset%3A%208,2%20or%20Grade%203%20event%29)

> “5% of patients taking Verzenio + ET discontinued treatment due to diarrhea. 20% of patients had a dose interruption, and 17% of patients had a dose reduction due to diarrhea.<sup>3</sup>”

Source: [VERZENIO: Diarrhea Management | HCP Safety, captured 2026-11-14](https://verzenio.lilly.com/hcp/safety-managing-diarrhea#:~:text=5%25%20of%20patients%20taking%20Verzenio%20%2B%20ET%20discontinued,a%20dose%20reduction%20due%20to)

Note: These figures are presented on the managing diarrhea page of the Verzenio HCP site for patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer in monarchE.

## Warnings

<a id="verzenio-lung-ild"></a>

### Can Verzenio cause lung problems (ILD or pneumonitis)?

> “Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with VERZENIO and other CDK4/6 inhibitors. In VERZENIO-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Severe%2C%20life%2Dthreatening%2C%20or%20fatal%20interstitial,there%20was%20one%20fatality%20%280.1%25%29.)

> “Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported [see Adverse Reactions (6.2)].”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Additional%20cases%20of%20ILD%20or,reported%20%5Bsee%20Adverse%20Reactions%20%286.2%29%5D.)

> “Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Monitor%20patients%20for%20pulmonary%20symptoms,by%20means%20of%20appropriate%20investigations.)

> “Table 5: VERZENIO Dosage Modifications and Management — Interstitial Lung Disease/Pneumonitis
> CTCAE Grade	VERZENIO Dosage Modifications
> Grade 1 or 2	No dosage modification is required.
> Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1	Withhold until toxicity resolves to baseline or ≤Grade 1.
> Resume at next lower dose.
> Grade 3 or 4	Discontinue VERZENIO.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%205%3A%20VERZENIO%20Dosage%20Modifications,Discontinue%20VERZENIO.)

<a id="verzenio-blood-clots"></a>

### Does Verzenio increase the risk of blood clots (VTE)?

> “Across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3), venous thromboembolic (VTE) events occurred in 2% to 5% of patients treated with VERZENIO. VTE events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, inferior vena cava thrombosis, jugular vein thrombosis, peripheral vein thrombosis and superficial vein thrombosis. In clinical trials, deaths due to VTE occurred in patients treated with VERZENIO.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=5.5%20Venous%20Thromboembolism-,Across%20four%20clinical%20trials%20in%203767%20patients%20%28monarchE%2C%20MONARCH%202%2C,in%20patients%20treated%20with%20VERZENIO.)

> “VERZENIO has not been studied in patients with early breast cancer who had a history of VTE. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=VERZENIO%20has%20not%20been%20studied,and%20treat%20as%20medically%20appropriate.)

> “Early Breast Cancer
> Any Grade	Withhold and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=VERZENIO%20Dosage%20Modifications-,Early%20Breast%20Cancer,the%20patient%20is%20clinically%20stable.)

> “Clinically relevant adverse reactions in <10% of patients who received VERZENIO in combination with tamoxifen or an aromatase inhibitor in monarchE include: pruritus (9%), dyspepsia (8%), nail disorder (6%), increased lacrimation (6%), dysgeusia (5%), ILD/pneumonitis (3%), and VTE (3%).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Clinically%20relevant%20adverse%20reactions%20in,ILD%2Fpneumonitis%20%283%25%29%2C%20and%20VTE%20%283%25%29.)

Note: MONARCH 2, MONARCH 3, and EMBER-3 are trials in advanced or metastatic breast cancer (section 5.3 of the Prescribing Information); the monarchE rate is in the last passage.

## Related pages
- [Medical information: Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/guidelines)
